BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 18052412)

  • 1. Aripiprazole: in adolescents with schizophrenia.
    Sanford M; Keating GM
    Paediatr Drugs; 2007; 9(6):419-23. PubMed ID: 18052412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.
    Findling RL; Robb A; Nyilas M; Forbes RA; Jin N; Ivanova S; Marcus R; McQuade RD; Iwamoto T; Carson WH
    Am J Psychiatry; 2008 Nov; 165(11):1432-41. PubMed ID: 18765484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
    McEvoy JP; Daniel DG; Carson WH; McQuade RD; Marcus RN
    J Psychiatr Res; 2007 Dec; 41(11):895-905. PubMed ID: 17631314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
    Kane JM; Carson WH; Saha AR; McQuade RD; Ingenito GG; Zimbroff DL; Ali MW
    J Clin Psychiatry; 2002 Sep; 63(9):763-71. PubMed ID: 12363115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: post hoc analysis of randomized clinical trial data.
    Robb AS; Carson WH; Nyilas M; Ali M; Forbes RA; Iwamoto T; Assunção-Talbott S; Whitehead R; Pikalov A
    J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):33-8. PubMed ID: 20166794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients.
    Takekita Y; Kato M; Wakeno M; Sakai S; Suwa A; Nishida K; Okugawa G; Kinoshita T
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():110-4. PubMed ID: 23022672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial.
    Tran-Johnson TK; Sack DA; Marcus RN; Auby P; McQuade RD; Oren DA
    J Clin Psychiatry; 2007 Jan; 68(1):111-9. PubMed ID: 17284138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
    Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.
    Kane JM; Sanchez R; Perry PP; Jin N; Johnson BR; Forbes RA; McQuade RD; Carson WH; Fleischhacker WW
    J Clin Psychiatry; 2012 May; 73(5):617-24. PubMed ID: 22697189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol.
    Andrezina R; Josiassen RC; Marcus RN; Oren DA; Manos G; Stock E; Carson WH; Iwamoto T
    Psychopharmacology (Berl); 2006 Oct; 188(3):281-92. PubMed ID: 16953381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
    Glick ID; Mankoski R; Eudicone JM; Marcus RN; Tran QV; Assunção-Talbott S
    J Affect Disord; 2009 May; 115(1-2):18-26. PubMed ID: 19230981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.
    Mintzer JE; Tune LE; Breder CD; Swanink R; Marcus RN; McQuade RD; Forbes A
    Am J Geriatr Psychiatry; 2007 Nov; 15(11):918-31. PubMed ID: 17974864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.
    Pigott TA; Carson WH; Saha AR; Torbeyns AF; Stock EG; Ingenito GG;
    J Clin Psychiatry; 2003 Sep; 64(9):1048-56. PubMed ID: 14628980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study.
    Kane JM; Peters-Strickland T; Baker RA; Hertel P; Eramo A; Jin N; Perry PP; Gara M; McQuade RD; Carson WH; Sanchez R
    J Clin Psychiatry; 2014 Nov; 75(11):1254-60. PubMed ID: 25188501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia.
    Cutler AJ; Marcus RN; Hardy SA; O'Donnell A; Carson WH; McQuade RD
    CNS Spectr; 2006 Sep; 11(9):691-702; quiz 719. PubMed ID: 16946694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early antipsychotic response to aripiprazole in adolescents with schizophrenia: predictive value for clinical outcomes.
    Correll CU; Zhao J; Carson W; Marcus R; McQuade R; Forbes RA; Mankoski R
    J Am Acad Child Adolesc Psychiatry; 2013 Jul; 52(7):689-698.e3. PubMed ID: 23800482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial.
    Li H; Luo J; Wang C; Xie S; Xu X; Wang X; Yu W; Gu N; Kane JM
    Schizophr Res; 2014 Aug; 157(1-3):112-9. PubMed ID: 24994555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study.
    Casey DE; Carson WH; Saha AR; Liebeskind A; Ali MW; Jody D; Ingenito GG;
    Psychopharmacology (Berl); 2003 Apr; 166(4):391-9. PubMed ID: 12610718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study.
    De Deyn P; Jeste DV; Swanink R; Kostic D; Breder C; Carson WH; Iwamoto T
    J Clin Psychopharmacol; 2005 Oct; 25(5):463-7. PubMed ID: 16160622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.